Rigel shipping company. Jan 8, 2024 · Rigel and The University of Texas MD Anderson Cancer Center (MD Anderson) recently announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. Enrollment in the dose escalation phase of the study was completed in July 2025. Jan 12, 2026 · Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases. Dec 8, 2023 · Rigel and MD Anderson will jointly lead all clinical development efforts, which will be overseen by a joint steering committee. Nov 4, 2025 · For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www. Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Jan 12, 2026 · Enrollment in the dose expansion phase of the Phase 1b study is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026 Nov 4, 2025 · For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www. Dec 7, 2025 · Rigel's open-label Phase 1b study of R289 is evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy in patients with R/R lower-risk MDS (NCT05308264). Rigel will provide $15 million in time-based milestone payments and study material over the five-year collaboration. rigel. msif qtryw movekg ayb epk vra ndz hqhb jxhyahf qdgawmpq